Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$193.61
$158.18
$64.80
$200.00
$7.80B-1.23203,884 shs735,521 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.97
$103.12
$49.67
$111.86
$6.59B-0.031.39 million shs859,895 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$68.66
$78.51
$21.15
$93.61
$6.15B0.531.59 million shs900,232 shs
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
$12.09
-0.2%
$9.55
$4.62
$13.28
$2.33BN/A1.25 million shs1.34 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%+27.61%+18.74%+38.66%+194.51%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.00%+0.20%+0.02%+0.96%+84.42%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+1.43%-23.90%+7.45%+137.99%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
0.00%+1.77%+38.01%+1,208,999,900.00%+1,208,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$193.61
$158.18
$64.80
$200.00
$7.80B-1.23203,884 shs735,521 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.97
$103.12
$49.67
$111.86
$6.59B-0.031.39 million shs859,895 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$68.66
$78.51
$21.15
$93.61
$6.15B0.531.59 million shs900,232 shs
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
$12.09
-0.2%
$9.55
$4.62
$13.28
$2.33BN/A1.25 million shs1.34 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%+27.61%+18.74%+38.66%+194.51%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.00%+0.20%+0.02%+0.96%+84.42%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+1.43%-23.90%+7.45%+137.99%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
0.00%+1.77%+38.01%+1,208,999,900.00%+1,208,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.80
Moderate Buy$214.6410.86% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.29
Hold$108.117.07% Upside
Liquidia Corporation stock logo
LQDA
Liquidia
2.45
Hold$98.0842.85% Upside
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
2.00
Hold$15.0024.07% Upside

Current Analyst Ratings Breakdown

Latest TRLV, LNTH, BLTE, and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Initiated CoverageBuy$303.00
9/4/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
UpgradeStrong-Buy
9/3/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy
9/3/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy
8/27/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
UpgradeHold (C)Hold (C+)
8/18/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
DowngradeStrong-BuyHold
8/17/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
DowngradeBuyHold
8/14/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Boost Price TargetOverweight$201.00 ➝ $206.00
8/14/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy
8/14/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Set Price Target$220.00
8/13/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
DowngradeHold (C+)Hold (C)
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B4.27$6.39 per share15.81$16.43 per share6.15
Liquidia Corporation stock logo
LQDA
Liquidia
$158.32M38.82N/AN/A$0.51 per share134.63
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.73N/A212.76N/AN/A-11.84%-11.62%11/9/2026 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$233.56M$4.1424.3918.49N/A17.69%28.10%14.35%11/5/2026 (Estimated)
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M$1.3750.1215.68N/A30.74%149.65%36.30%11/2/2026 (Estimated)
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
N/AN/AN/A21.21N/AN/AN/AN/AN/A

Latest TRLV, LNTH, BLTE, and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.73-$0.54+$0.19-$0.70N/AN/A
8/12/2026Q2 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.7580$0.74-$0.0180$0.74$168.48 million$171.68 million
8/7/2026Q2 2026
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
$0.06$0.11+$0.05-$2.10$268.82 million$271.00 million
8/6/2026Q2 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.30$1.55+$0.25$1.11$363.23 million$388.18 million
6/30/2026Q2 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A-$0.54N/A-$0.70N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
33.56
33.56
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.43
3.06
2.89
Liquidia Corporation stock logo
LQDA
Liquidia
0.63
2.31
2.12
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
N/A

Insider Ownership

CompanyInsider Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.70%
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
3.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1040.27 million34.92 millionNot Optionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1,19365.27 million64.16 millionOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
5089.51 million66.60 millionOptionable
Trulieve Cannabis Corp. stock logo
TRLV
Trulieve Cannabis
5,000192.57 million185.27 millionN/A

Recent News About These Companies

Cannabis Stocks To Consider - August 31st
Trulieve Announces September 2026 Event Participation
Cannabis Stocks Worth Watching - August 30th
3 Marijuana Stocks To Focus On For Future Growth And Profits
Cannabis Stocks To Watch Now - August 29th
Cannabis Stocks To Follow Now - August 26th
3 Marijuana Stocks For Investors To Consider
Trulieve Cannabis Q2 Earnings Call Highlights
Trulieve: Q2 Earnings Snapshot
Trulieve Reports Second Quarter 2026 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$193.61 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$100.97 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$68.66 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Trulieve Cannabis stock logo

Trulieve Cannabis NYSE:TRLV

$12.09 -0.02 (-0.17%)
As of 09/4/2026 03:58 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.